Tredje AP fonden Purchases 20,576 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Tredje AP fonden raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 172.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,505 shares of the medical equipment provider’s stock after acquiring an additional 20,576 shares during the period. Tredje AP fonden’s holdings in Zimmer Biomet were worth $3,528,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. OLD Point Trust & Financial Services N A bought a new stake in Zimmer Biomet during the 4th quarter valued at approximately $26,000. Ables Iannone Moore & Associates Inc. bought a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $30,000. Crewe Advisors LLC bought a new stake in shares of Zimmer Biomet in the first quarter valued at approximately $31,000. Family Firm Inc. acquired a new stake in shares of Zimmer Biomet in the second quarter worth $33,000. Finally, J.Safra Asset Management Corp increased its holdings in shares of Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 235 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 0.1 %

Shares of ZBH opened at $106.34 on Thursday. The stock’s fifty day simple moving average is $109.92 and its 200-day simple moving average is $115.72. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $21.66 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same quarter last year, the firm earned $1.82 EPS. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.02 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 20.78%.

Analysts Set New Price Targets

A number of research firms recently weighed in on ZBH. Oppenheimer decreased their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. JPMorgan Chase & Co. lowered their target price on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research note on Monday. Piper Sandler cut shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $140.00 to $115.00 in a research note on Monday, July 1st. Robert W. Baird lowered their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Finally, Royal Bank of Canada cut their target price on Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $125.17.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.